Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast

[News]

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer.

More... (http://www.news-medical.net/news/20101203/Geron-commences-enrollment-in-imetelstat-Phase-2-clinical-trial-for-metastatic-breast-cancer.aspx)